[Current treatment strategies for diffuse large B-cell lymphoma]
Related Experiment Video
Updated: Oct 30, 2026

Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
Hideki Goto1,2
1Department of Hematology, Hokkaido University Hospital.
Abstract:
Diffuse large B-cell lymphoma (DLBCL) is potentially curable with frontline immunochemotherapy; however, some patients develop relapsed or refractory disease. Recently, chimeric antigen receptor T-cell (CAR T-cell) therapy and bispecific antibodies have emerged as effective immunotherapeutic approaches for relapsed or refractory DLBCL, transforming the conventional treatment paradigm. Moreover, several novel agents are under active clinical development. This review summarizes recent advances in treatment strategies for DLBCL and discusses future perspectives.
Related Concept Videos
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)